Physician profile
Allison Mitchell
NPI 1407364862
$2,828.26
in general payments reported to CMS, 2019-2025
24 companies · $620 in 2025
The $620 reported for 2025 was more than what 77% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $469 · 2023: $955 · 2024: $637 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,199 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.93 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $383.77 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $369.68 | 2022-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $336.62 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $255.94 | 2022-2024 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $195.03 | 2021-2025 | Acthar |
| Amgen INC. | $175.25 | 2022-2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $152.80 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.71 | 2023-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $139.52 | 2024-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals Lp | $132.38 | 2023-2025 | Farxiga |
| Novo Nordisk INC | $115.43 | 2024-2025 | Rivfloza |
| Otsuka America Pharmaceutical, INC. | $91.90 | 2024-2025 | Jynarque, Voyxact |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $59.08 | 2023 | Lifevest |
| Travere Therapeutics, INC. | $46.33 | 2023 | |
| Scpharmaceuticals INC. | $42.25 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $34.90 | 2022 | |
| Genentech USA, INC. | $22.72 | 2025 | Gazyva |
| Janssen Biotech, INC. | $22.24 | 2024 | Tremfya |
| Akebia Therapeutics INC | $22.17 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.85 | 2023 | Ultomiris |
| Abbott Laboratories | $18.58 | 2023 | Ensite |
| W. L. Gore & Associates, INC. | $16.44 | 2022 | |
| Opko Pharmaceuticals, LLC | $15.52 | 2024 | Rayaldee |
| Lilly USA, LLC | $14.15 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.